MAIA Biotechnology (MAIA) Current Assets (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Current Assets for 6 consecutive years, with $28.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets rose 155.7% year-over-year to $28.2 million in Q2 2026; TTM through Jun 2026 was $28.2 million, a 155.7% increase from a year earlier, with the FY2025 full-year figure at $9.7 million, down 4.44% from the prior year.
• Current Assets was $28.2 million for Q2 2026 at MAIA Biotechnology, down from $35.3 million in the prior quarter.
• Over five years, Current Assets peaked at $35.3 million in Q1 2026 and troughed at $6.6 million in Q3 2023.
• A 5-year average of $12.7 million and a median of $10.2 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slumped 55.12% in 2023 and jumped 197.72% in 2026, its largest moves.
• Over 5 years, Current Assets stood at $11.8 million in 2022, then plunged by 35.94% to $7.6 million in 2023, then surged by 34.22% to $10.2 million in 2024, then declined by 4.44% to $9.7 million in 2025, then surged by 191.05% to $28.2 million in 2026.
• The last three Current Assets figures came in at $28.2 million (Q2 2026), $35.3 million (Q1 2026), and $9.7 million (Q4 2025), per Business Quant data.